The HPV vaccine is an impressive health multitasker. The vaccine, which targets the human papillomavirus, can help protect your kids from developing six types of cancer in adulthood. It's also highly ...

March 30, 2010 — The incidence of oropharyngeal carcinoma related to human papillomavirus (HPV) has been increasing in recent years, and there is speculation that this is the result of the "sexual ...

Please provide your email address to receive an email when new articles are posted on . Zhang and colleagues obtained data from the Surveillance, Epidemiology, and End Results program from 69,562 ...

DelveInsight's HPV+ Oropharyngeal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, HPV+ oropharyngeal cancer emerging drugs, market share of ...

A rapid rise in the rate of oropharyngeal cancer among men is being linked to human papillomavirus (HPV), and the number of cases in the U.S. could increase by almost 30% by 2020, surpassing the ...

Human papillomavirus–associated oropharynx cancer (HPVA-OPC) is rapidly increasing in incidence and has unique epidemiologic, molecular, and biologic characteristics. Despite being recognized as ...

Although the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with ...

Oropharynx cancer (OPC) constitutes the most common location for squamous-cell head and neck cancer, and most OPC is caused by the human papilloma virus (HPV). Early-stage (American Joint Committee on ...

Munich, Germany, 22 October 2018 - Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking ...

Oropharyngeal squamous cell carcinoma (SCC) is now the most common HPV-associated cancer in the United States, according to a new report from the Centers for Disease Control and Prevention (CDC) that ...

The HPV+ oropharyngeal cancer market is expanding rapidly, driven by a rising incidence of HPV-driven OPSCC and growing clinician awareness. The anticipated launch of emerging therapies such as Merck ...